Regeneron Pharmaceuticals Inc (REGN)

Days of sales outstanding (DSO)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Receivables turnover		2.28	2.26	2.35	2.49	2.30	2.33	2.46	2.40	2.27	2.46	2.75	3.40	2.65	2.48	1.76	2.19	2.72	2.31	3.35	3.14
DSO	days	159.83	161.38	155.30	146.30	158.58	156.49	148.34	151.82	160.56	148.32	132.93	107.36	137.58	147.41	207.20	166.52	134.32	158.13	108.94	116.11

December 31, 2024 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 2.28
= 159.83

Days Sales Outstanding (DSO) is a key financial metric that measures the average number of days it takes for a company to collect revenue after a sale is made. In the case of Regeneron Pharmaceuticals Inc, the DSO trend over the past several quarters shows fluctuations in the collection period.

From March 31, 2020, to June 30, 2020, the DSO decreased from 116.11 days to 108.94 days, indicating an improvement in the company's ability to collect receivables. However, there was a significant increase in DSO to 158.13 days by September 30, 2020, suggesting a potential slowdown in collections.

Subsequently, the DSO fluctuated between 134.32 days and 166.52 days until March 31, 2021, before rising sharply to 207.20 days by June 30, 2021. This spike in DSO may indicate challenges in collecting revenue efficiently. The DSO then decreased to 147.41 days by September 30, 2021, before stabilizing around 137-155 days until June 30, 2024.

Overall, the DSO trend for Regeneron Pharmaceuticals Inc signals some variability in the collection period, with periodic increases and decreases. It is essential for the company to monitor and manage its DSO effectively to ensure efficient cash flow management and timely collection of revenue.